Pharnext SA
Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company's products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer's disease, as well as Parkinson's disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France. Show More...
-
Website https://www.pharnext.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 0.00 EUR
-
Last Updated 14-02-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share EUR -1.45 -1.67 -1.7 -2.1 -2.0 -2.0 -2.0 -2.0 Dividends EUR Payout Ratio % * Shares Mil 6.0 6.0 6.0 8.0 11.0 12.0 15.0 15.0 Book Value Per Share * EUR -2.92 -0.57 -1.18 0.25 -0.43 Free Cash Flow Per Share * EUR -1.24 -1.96 -1.22 -1.47 Return on Assets % -75.3 -114.95 -134.24 -120.44 -96.3 -84.75 -86.06 -86.06 Financial Leverage (Average) 5.98 Return on Equity % Return on Invested Capital % Interest Coverage -100.36 -7.28 -8.85 -8.53 -15.5 -6.49 -9.28 -9.28 Current Ratio 1.36 0.63 0.31 2.29 2.36 3.17 2.17 2.17 Quick Ratio 1.24 0.6 0.27 2.24 2.28 3.08 2.04 2.04 Debt/Equity 2.3